CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and moderate symptoms of COVID...
Phase 2
Durham, North Carolina, United States and 6 other locations
multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and severe symptoms of COVID...
Phase 2
Durham, North Carolina, United States and 6 other locations
vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19).In order to represent a more recently circulating SAR...
Phase 2
Durham, North Carolina, United States and 144 other locations
seek to enroll immunocompromised patients with Lower Tract parainfluenza infection.It also contains a sub-study to enroll patients with severe COVID...
Phase 3
Durham, North Carolina, United States and 66 other locations
study treatment works in the study) of the study medicine (called nirmatrelvir/ritonavir) for potential treatment of coronavirus disease 2019 (COVID...
Phase 3
Chapel Hill, North Carolina, United States and 75 other locations
studies or substudies based on age group and prior history of COVID-19 vaccinations. All participants in each of the 5 sub-studies ...
Phase 3
Durham, North Carolina, United States and 100 other locations
the efficacy and safety of mRNA-1283 and mRNA-1273 (variant formulations) in adults 50 to 64 years of age without high risk factors for severe COVID...
Phase 4
Durham, North Carolina, United States and 149 other locations
against infection with SARS-CoV-2, the novel coronavirus causing COVID-19 disease. The investigational vaccine, MV-014-212, is a li...
Phase 1
Raleigh, North Carolina, United States and 1 other location
This study is designed to find out how well the COVID-19 vaccine protects people 50 to 64, who don't have any serious health proble-...
Phase 3
Durham, North Carolina, United States and 199 other locations
This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity an...
Phase 2, Phase 3
Raleigh, North Carolina, United States and 90 other locations
Clinical trials
Research sites
Resources
Legal